Vetanco International Acknowledgment for Sherry Layton, Vetanco Scientific Director

Sherry Layton, Vetanco Scientific Director, will be awarded in the 12th International Conference on Emerging Infectious Diseases

Vetanco Sherry Layton, Vetanco USA Inc. CSO, was invited to give a presentation at Vaccines 2020 - Vetanco

Frontiers Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

New Trends in Vaccine Development

Frontiers Evaluation of a Novel Mucosal Administered Subunit Vaccine on Colostrum IgA and Serum IgG in Sows and Control of Enterotoxigenic Escherichia coli in Neonatal and Weanling Piglets: Proof of Concept

Vetanco BV Science, Inc.; a strategic move by Vetanco and Dr. Bata in the United States - Vetanco

Frontiers A Role for the Non-Canonical Wnt-β-Catenin and TGF-β Signaling Pathways in the Induction of Tolerance during the Establishment of a Salmonella enterica Serovar Enteritidis Persistent Cecal Infection in Chickens

Diretora de Biotecnologia da Vetanco/BV Science no European Animal Microbiome Congress – O Presente Rural

Sherry Layton - Chief Executive Officer - Vetanco USA

PDF) Role of Gut Microbiota in Cardiovascular Disease that Links to Host Genotype and Diet

Vaccines Conference-2022, Global Conference on Vaccines Research and Development

Vaccines Conference-2022, Global Conference on Vaccines Research and Development

PDF) Host genotype affects endotoxin release in excreta of broilers at slaughter age

Frontiers Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

PDF) Development and initial evaluation of a candidate Clostridium perfringens a toxin-based necrotic enteritis vaccine utilizing recombinant Salmonella as a vaccine vector